COMMUNIQUÉS West-GlobeNewswire
-
SIGA Announces Retirement of Chief Scientific Officer Dennis Hruby, Ph.D.
09/11/2026 -
IRulya Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
09/11/2026 -
SodaPeak Launch 2026 Advanced Soda Peak Gummies for Male Vitality and Energy Supplement New Information For Multi-Ingredient And Benefits.
09/11/2026 -
Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder
09/11/2026 -
Solana Company to Release Third Quarter 2026 Operating Results on November 11, 2026
09/11/2026 -
Zealand Pharma to participate in the Jefferies Global Healthcare Conference
09/11/2026 -
Kyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA Neurology
09/11/2026 -
Vistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety Disorder
09/11/2026 -
Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting
09/11/2026 -
SAB BIO to Participate in Upcoming Investor Conferences
09/11/2026 -
New Data at 2026 American Heart Association Scientific Sessions Highlight Cardiovascular Effects of Sotagliflozin on Thrombus Formation and in Hypertrophic Cardiomyopathy
09/11/2026 -
Santa Ana Bio Presents Preclinical Data on SAB05, a CD40-Targeted Glucocorticoid Antibody-Drug Conjugate, at ACR Convergence 2026
09/11/2026 -
NKGen Biotech to Present Long-Term Follow-Up of Troculeucel in Moderate Alzheimer’s Disease at CTAD 2026
09/11/2026 -
Tevogen Complements Capital Access with Two-Year Extension to Loan Agreement
09/11/2026 -
Evaxion files amendment to registration statement related to 2025 EIB debt settlement agreement
09/11/2026 -
Novastra Therapeutics Reports Further Encouraging Clinical Data for Its Novel XIRT™/OAP Cancer Immune Therapy at SITC 2026
09/11/2026 -
Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease
09/11/2026 -
Hinge Bio Shares Encouraging Clinical Data for HB2198, a Novel B-Cell Depleting Agent for Treating Autoimmune Disease, at ACR Convergence 2026
09/11/2026 -
NTG Nordic Transport Group publishes interim report for Q3 2026
09/11/2026
Pages